• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A Systematic Assessment of the Epidemiologic Literature Regarding an Association between Acetaminophen Exposure and Cancer
The objective of this publication is to analyze the results of these epidemiologic studies using a framework that accounts for the inherent challenge of evaluating acetaminophen, including, broad population-wide use in multiple disease states, challenges with exposure measurement, protopathic bias, channeling bias, and recall bias. When evaluated using this framework, the data do not support a causal association between acetaminophen use and cancer.PMID:34517075 | DOI:10.1016/j.yrtph.2021.105043
Source: Regulatory Toxicology and Pharmacology : RTP - September 13, 2021 Category: Toxicology Authors: Rachel Weinstein Amisha M Parikh-Das Raymark Salonga Martijn Schuemie Patrick B Ryan Evren Atillasoy Anne Vosatka Gary Eichenbaum Jesse A Berlin Source Type: research

Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails
Conclusions: Nivolumab and pembrolizumab have promising outcomes with tolerable AEs and drug-related deaths in patients with relapsed or refractory lymphoma. Pembrolizumab caused less any grade AEs like fatigue and rash than nivolumab. Patients with HL got better response than NHL. Introduction Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor mainly expressed on activated T cells, natural killer cells, and B cells (Ishida et al., 1992). The PD-L1 and PD-L2 are its known ligands, which interact with PD-1 on T cells and prevent T-cell activation and proliferation. PD-L1 is expressed on macropha...
Source: Frontiers in Pharmacology - April 30, 2019 Category: Drugs & Pharmacology Source Type: research